BACKGROUND
Family screening is recommended in dilated cardiomyopathy (DCM), but risk stratification of relatives of probands without pathogenic or likely pathogenic variants (gene-elusive) remains uncertain.
OBJECTIVES
This study sought to define the incidence, prognosis, and predictors of disease development in firs...
A. Paldino, E. Del Mestre, I. Gandin et al.· JACC. Heart failure· 0 citations
Disease-modifying therapies for transthyretin amyloid cardiomyopathy (ATTR-CM) improve clinical outcomes, yet older patients are undertreated. In this analysis, we evaluated survival and cardiovascular-related hospitalizations (CVH) among patients treated with tafamidis (tafamidis free acid at 61 mg or bioequivalent ta...
C. Fumagalli, F. Cappelli, M. Maurer et al.· Cardiology and Therapy· 0 citations
BACKGROUND
Cardiomyopathy guidelines recommend routine screening of at-risk relatives with dilated cardiomyopathy (DCM). Titin-truncating variants are the most prevalent cause. However, the diagnostic yield of screening is low. Risk-based stratification could optimize screening intervals and resource allocation. This s...
S. Muller, N. Beelen, A. Paldino et al.· Circulation: Heart Failure· 0 citations
These findings support MVA multiparametric prediction over the traditional left ventricular ejection fraction ≤35% threshold and allow clinically meaningful arrhythmic risk classification in patients with nonischemic dilated cardiomyopathy.
Noemí Ramos-López, N. Mora-Ayestarán, Juan Pablo Ochoa et al.· Circulation· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
